<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120129008863N17</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-25</date_registration>
      <primary_sponsor>Vice Presidency for Research and Technology, Hakim Sabzevari University</primary_sponsor>
      <public_title>Comparative Effects of Small-Sided Games with and without Coenzyme Q10 Supplementation on Oxidative Stress Markers</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Effects of Small-Sided Games with and without Coenzyme Q10 Supplementation on Oxidative Stress Markers in Soccer Players</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92728</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Health service research, Randomization description: This study utilizes a simple individual-level randomization method, where 20 participants are randomly assigned to two groups (high-intensity interval training with CoQ10 supplementation and training with placebo). A computer-generated sequence is used for random allocation to ensure high precision and reproducibility while minimizing selection bias, Blinding description: This study is a single-blind clinical trial in which blinding applies exclusively to the CoQ10 and placebo administration. Participants read the research protocol during the first session, and the supplement and placebo, provided in identical capsules, are distributed among them such that only the researcher is aware of the capsule contents.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Inflammation in Football Players.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention Group 1 (Training + Supplementation): Participants in this group will engage in a 6-week small-sided games training program while receiving the active supplement. The training protocol consists of three sessions per week, with each session lasting 60 minutes in total (including a 10-minute warm-up, 40 minutes of main training, and a 10-minute cool-down). Concurrently, subjects will consume one 100 mg CoQ10 capsule daily (manufactured by Rosedarou Pharmaceutical Co., Iran) approximately 2 to 4 hours prior to exercise. All training sessions will be conducted under the direct supervision of a certified coach. Intervention 2: Control group: Intervention Group 2 (Training + Placebo): Participants in this group will perform the identical 6-week small-sided games training protocol (3 sessions per week, 60 minutes per session). Instead of CoQ10, they will consume one placebo capsule daily (containing canola oil, manufactured by Rosedarou Pharmaceutical Co., Iran). The placebo capsules are identical in physical appearance to the CoQ10 capsules to maintain blinding. All training sessions will be conducted under the direct supervision of a certified coach to ensure safety and protocol adherence.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The reasons for the current refusal to share Individual Participant Data (IPD) are: Preserving Confidentiality: Ensuring the highest level of confidentiality and privacy for the participants, which is the principal priority of the research team. Resource Constraints: The lack of adequate financial and human resources to perform the complex processes of preparing, standardizing, and completely anonymizing the raw data sets.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Keyvan Hejazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hakim Sabzevari University Campus, Tohid Town, Sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9617976487</zip>
        <telephone>+98 51 4401 2767</telephone>
        <email>k.hejazi@hsu.ac.ir</email>
        <affiliation>Hakim Sabzevari University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Keyvan Hejazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hakim Sabzevari University Campus, Tohid Town, Sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9617976487</zip>
        <telephone>+98 51 4401 2767</telephone>
        <email>k.hejazi@hsu.ac.ir</email>
        <affiliation>Hakim Sabzevari University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having at least 2 years of continuous and organized participation in soccer
Being in full physical health (confirmed by the PAR-Q health questionnaire)
No consumption of any antioxidant, vitamin, or anti-inflammatory supplements within 3 months prior to the study
Adherence to a regular diet and non-use of tobacco and alcohol</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>20 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Absence from more than two consecutive sessions or 10% of total training sessions
Significant dietary changes or unauthorized use of ergogenic supplements during the intervention period
Occurrence of sports injuries preventing continuation of the training protocol
Contracting infectious or viral illnesses during the study period that could alter inflammatory and oxidative markers.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z00.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for examination for normal comparison and control in clinical research program</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention Group 1 (Training + Supplementation): Participants in this group will engage in a 6-week small-sided games training program while receiving the active supplement. The training protocol consists of three sessions per week, with each session lasting 60 minutes in total (including a 10-minute warm-up, 40 minutes of main training, and a 10-minute cool-down). Concurrently, subjects will consume one 100 mg CoQ10 capsule daily (manufactured by Rosedarou Pharmaceutical Co., Iran) approximately 2 to 4 hours prior to exercise. All training sessions will be conducted under the direct supervision of a certified coach.</i_keyword>
      <i_keyword>Control group: Intervention Group 2 (Training + Placebo): Participants in this group will perform the identical 6-week small-sided games training protocol (3 sessions per week, 60 minutes per session). Instead of CoQ10, they will consume one placebo capsule daily (containing canola oil, manufactured by Rosedarou Pharmaceutical Co., Iran). The placebo capsules are identical in physical appearance to the CoQ10 capsules to maintain blinding. All training sessions will be conducted under the direct supervision of a certified coach to ensure safety and protocol adherence.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Glutathione peroxidase. Timepoint: Before the exercise intervention and 6 weeks after the intervention. Method of measurement: Laboratory method: Enzyme-Linked Immunosorbent Assay, using the ZellBio kit (mmol/L).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total Antioxidant Capacity. Timepoint: Before the exercise intervention and 6 weeks after the intervention. Method of measurement: Laboratory method: Enzyme-Linked Immunosorbent Assay, using the ZellBio kit (mmol/L).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Presidency for Research and Technology, Hakim Sabzevari University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-31</approval_date>
        <contact_name>Hakim Sabzevari University</contact_name>
        <contact_address>Hakim Sabzevari University, Tohid Shahr, Sabzevar; Department of Sport Sciences Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
